We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLIN
Clinigen Group plc
29 November 2021
29 November 2021
Clinigen signs agreement with Nippon Shinyaku for
Viltolarsen Managed Access Program
Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical Services and Products company, announces it has signed an exclusive agreement with Nippon Shinyaku Co., Ltd ('Nippon Shinyaku') to implement a Managed Access Program for VILTEPSO(R) ( viltolarsen ) for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping therapy.
DMD is a progressive muscle disease that primarily occurs in boys due to a genetic mutation in the dystrophin gene. This prevents the production of normal dystrophin resulting in reduced muscle strength/function that progressively continues to decline. There are many types of genetic mutations that can cause DMD. Viltolarsen skips exon 53; and therefore has the potential to rescue the dystrophin protein for 8-10% of DMD patients.(1)
Following finalization, the Managed Access Program will enable early access to VILTEPSO (R) for eligible patients in countries where it is not commercially available. VILTEPSO (R) is currently only approved in the US and Japan.
Under the terms of the agreement, Clinigen will manage key elements of the program including regulatory oversight, logistics and access management.
Pete Belden, Executive Vice President Services Division, Clinigen, said:
"We are pleased to partner with Nippon Shinyaku to enable access to a valuable new treatment option for DMD, a rare and progressive disease for which there remains a clear unmet medical need. This agreement underlines Clinigen's strength in partnering with biotechnology companies to provide services that enable quicker and broader access to new innovative therapies ."
Kazuchika Takagaki, Director, Head of R&D, Nippon Shinyaku, said:
"We are delighted to help more DMD patients with critical unmet medical needs around the world on this important access program in partnership with Clinigen . We look forward to further contributing to the well-being of patients and their families."
Healthcare professionals can obtain details about the VILTEPSO(R) Program by calling the customer service team
at +44 1932 824001 or emailing medicineaccess@clinigengroup.com .
Patients seeking medical information should contact their physician.
- Ends -
Contact details
Clinigen Group plc +44 (0) 1283 495010 Pete Belden, EVP Services Division investors@clinigengroup.com Rob Fox, VP Investor Relations and Corporate Development Consilium Strategic Communications Mary-Jane Elliott / Matthew Cole / Jessica Tel: +44 (0) 20 3709 5700 Hodgson Clinigen@consilium-comms.com Nippon Shinyaku Co., Ltd. Corporate Communications Dept. Fax: +81-75-321-9128 kouhou@mb.nippon-shinyaku.co.jp
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products company focused on providing ethical access to medicines. Its' mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 20,000 healthcare professionals across more than 120 countries.
For more information on Clinigen, please visit http://www.clinigen.com
About Nippon Shinyaku
Nippon Shinyaku's mission is to help people lead healthier and happier lives. Through creating unique medicines that will bring hope to patients and families struggling with illness, we aim to be an organization trusted by the community. Please visit their website (http://www.nipponshinyaku.co.jp/english/) for products or detailed information.
Duchenne Muscular Dystrophy (DMD)
The incidence of DMD is reported as being 10.7 to 27.8 per 100,000 live male births worldwide.(2) DMD is a progressive form of muscular dystrophy that occurs primarily in males. DMD causes progressive weakness and loss of skeletal, cardiac, and pulmonary muscles. Early signs of DMD may include delayed ability to sit, stand or walk. There is a progressive loss of mobility, and by adolescence, patients with DMD may require the use of a wheelchair. Cardiac and respiratory muscle problems begin in the teenage years and lead to serious, life-threatening complications.
References
1. Komaki H, Takeshima Y, Matsumura T, Ozasa S, Funato M, Egawa Y, et al. (n.d.). A Japanese Phase I/II study of NS-065/ NCNP-01 (Viltolarsen), Exon 53 skipping drug, in patients with Duchenne muscular dystrophy-a dose-finding study. Mendoza: Poster presented at the 23rd International Annual Congress of
the World Muscle Society; 2018.
2. Mah, J.K.; Korngut, L.; Dykeman, J.; Day, L.; Pringsheim, T.; Jette, N. A systematic review and meta-analysis
on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul. Disord. 2014, 24, 482-491.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAFEWFWMEFSEDF
(END) Dow Jones Newswires
November 29, 2021 02:00 ET (07:00 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions